RxDoctor Payments Data

John Showalter, MD

Internal Medicine · Knoxville, TNNPI 1104862002

Payments from drug & device makers

$8,433in general payments, 2019–2025

Across 618 payments — averaging $13.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$1K
  • Novo Nordisk$989
  • Amgen$777
  • Abbott$590
  • Astellas Pharma US Inc$306
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,433100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,433 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$329,198
Medicare patients
531
Services billed
14,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide222$268,604
EliquisApixaban218$247,252
OzempicSemaglutide135$181,893
JardianceEmpagliflozin68$84,803
XareltoRivaroxaban50$61,254
TrulicityDulaglutide48$53,408
Tresiba Flextouch U-200Insulin Degludec30$44,468
InvokanaCanagliflozin12$20,663
Lantus SolostarInsulin Glargine,hum.Rec.Anlog80$17,134
FarxigaDapagliflozin Propanediol14$16,250
LinzessLinaclotide20$13,651
MyrbetriqMirabegron15$12,284
ShingrixVaricella-Zoster Ge/As01b/Pf32$7,300
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen372$6,189
Levothyroxine Sodium770$5,943

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$214$322,012270 claims
PfizerEliquis$1,025$247,252218 claims
Novo NordiskOzempic$989$181,893135 claims
Boehringer IngelheimJardiance$138$84,80368 claims
Johnson & JohnsonXarelto, Invokana$181$81,91662 claims
AbbVieLinzess, Synthroid$1,138$18,30798 claims
AstraZenecaFarxiga$296$16,25014 claims
Astellas Pharma US IncMyrbetriq$306$12,28415 claims
GSKShingrix$97$7,30032 claims
Sanofi-aventis U.S. LLCLantus$58$3,59025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →